Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on July 19, 2007
Schizophrenia Bulletin 2007 33(5):1120-1130; doi:10.1093/schbul/sbm083
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
33/5/1120    most recent
sbm083v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Buchanan, R. W.
Right arrow Articles by Lieberman, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buchanan, R. W.
Right arrow Articles by Lieberman, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia

Robert W. Buchanan1,2, Robert Freedman3, Daniel C. Javitt4, Anissa Abi-Dargham5 and Jeffrey A. Lieberman6
2 Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 2128
3 Department of Psychiatry, University of Colorado Health Sciences Center
4 Department of Psychiatry, Nathan Kline Institute for Psychiatric Research, New York University School of Medicine
5 Department of Psychiatry, New York State Psychiatric Institute
6 Department of Psychiatry, College of Physicians and Surgeons, Columbia University

1 To whom correspondence should be addressed; tel: 410-402-7876; fax: 410-402-7198; e-mail: rwbuchanan{at}mprc.umaryland.edu.

Wayne Fenton was a major driving force behind the establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project mechanisms. These projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified 3 drug mechanisms of particular interest: cholinergic, dopaminergic, and glutamatergic. The TURNS project is designed to select potential cognitive-enhancing agents and evaluate their potential efficacy in the context of proof of concept or clinical efficacy trials. This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms.

Keywords: cognitive impairments / nicotinic receptors / dopamine / glutamate


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Schizophr BullHome page
E. Ivleva, G. Thaker, and C. A. Tamminga
Comparing Genes and Phenomenology in the Major Psychoses: Schizophrenia and Bipolar 1 Disorder
Schizophr Bull, July 1, 2008; 34(4): 734 - 742.
[Full Text] [PDF]

Home page
 FocusHome page
Bibliography Schizophrenia
Focus, January 1, 2008; 6(2): 197 - 199.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.